operating performance and financial position for the third quarter and nine months ended September 30, 2018 with those of 2017. This report discusses principal changes in the unreviewed consolidated financial
operating performance and financial position for the third quarter and nine months ended September 30, 2018 with those of 2017. This report discusses principal changes in the reviewed consolidated financial
Company Limited and its subsidiaries (“the Company”) would like to clarify herewith the operating result for the year 2019 as follows:- Financial Position As at 31 December 2019, total consolidated assets
consolidated financial statements of the Company increased by Baht 201.68 million or 8.31% compared with last year. An increase mainly due to higher net accounts receivable of Baht 103.75 million since some
assets of consolidated financial statements increased by Baht 115.18 million or 4.7% compared with last year. An increase mainly arise from cash equivalents of Baht 32.77 million since cash paid-in for
the consolidated net debt to equity ratio was considerably low at 0.25 time. Overall Financial Performance and Profitability Business Segment of GFPT Group 2Q 2020 2Q 2019 Change 6M 2020 6M 2019 Change
position for the year 2017 with those of 2016. This report discusses principal changes in the unaudited consolidated financial statements. Overall market environment The Thai economy in 2017 showed clear
position for the year 2017 with those of 2016. This report discusses principal changes in the audited consolidated financial statements. Overall market environment The Thai economy in 2017 showed clear signs
financial position for the fourth quarter and year ended December 31, 2018 with those of 2017. This report discusses principal changes in the audited consolidated financial statements. Overall market
performance and financial position for the fourth quarter and year ended December 31, 2018 with those of 2017. This report discusses principal changes in the unaudited consolidated financial statements. Overall